Beta
ManageSearchChatDiscover
114305

Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis

Article

Last updated: 22 Jan 2023

OverviewSimilar Items

Subjects

-

Tags

Anti-cancer Immunotherapy
Cellular and molecular targeting
Inflammatory and cancer

Abstract

Background: A significant number of patients with hepatitis C virus (HCV) infection are at high risk of progressing to liver cirrhosis and hepatocellular carcinoma (HCC). The lack of noninvasive methods for assessment of the degree of liver damage is the main limitation in the clinical management of liver diseases. Aim: This study was conducted to evaluate the expression level of plasma miR-500 in HCV-induced fibrosis, cirrhosis and HCC patients. Methods and results: This prospective study involved 120 subjects, who were divided into 4 groups (n=30/group): healthy control, liver fibrosis patients, liver cirrhosis patients and HCC patients; all patients encountered in the work were clinically diagnosed as chronic HCV patients. The expression of miR-500 in plasma was asessed using quantitative real-time PCR, whereas serum alpha-fetoprotein (AFP) was measured using electrochemi-luminescence immunoassay. Results: The fold change in expression of plasma miR-500 showed significant up-regulation in cirrhotic patients more than 8 fold change as compared to fibrosis group. No significant fold changes in plasma miR-500 expression were found between either (HCC versus cirrhosis group) or (HCC versus fibrosis group. The serum level of AFP was 28.09 higher in the HCC group than non-HCC group.  Receiver operating characteristic curve (ROC) analysis indicated that the ideal cut-off values of the plasma miR-500 in both fibrosis and cirrhosis groups were 1.52 and 1.15, respectively and 8.2 and 4.55, respectively for AFP. Conclusion: Plasma miR-500 can be used as a novel biomarker for the differentiation between liver fibrosis and cirrhosis.

DOI

10.21608/jcbr.2020.39544.1062

Keywords

biomarkers, Hepatocellular carcinoma, Liver cirrhosis, Liver fibrosis, MicroRNA-500

Authors

First Name

Nahla

Last Name

El-Ashmawy

MiddleName

-

Affiliation

Department of Biochemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Email

nahla.elashmawi@pharm.tanta.edu.eg

City

-

Orcid

-

First Name

Ghada

Last Name

Al-Ashmawy

MiddleName

-

Affiliation

Department of Biochemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Email

ghadaashmawy@pharm.tanta.edu.eg

City

-

Orcid

0000-0003-2225-1671

First Name

Linda

Last Name

Zayed

MiddleName

-

Affiliation

Clinical Trial Unit & Bioequivalence Center, Egyptian Liver Research Institute and Hospital (ELRIAH), Cairo, Egypt

Email

lindazayed@yahoo.com

City

-

Orcid

-

First Name

Ayman

Last Name

Hassan

MiddleName

-

Affiliation

Molecular Biology Unit, Egyptian Liver Research Institute and Hospital, Cairo, Egypt

Email

ayman.hassan75@yahoo.com

City

-

Orcid

-

First Name

Reham

Last Name

Soliman

MiddleName

-

Affiliation

Tropical Medicine Department, Faculty of Medicine, Port Said University. and Egyptian Liver Research Institute and Hospital, Egypt

Email

rehamelsayed@hotmail.com

City

-

Orcid

-

First Name

Gamal

Last Name

Shiha

MiddleName

-

Affiliation

Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Email

g_shiha@hotmail.com

City

-

Orcid

-

Volume

5

Article Issue

2

Related Issue

24923

Issue Date

2021-06-01

Receive Date

2020-08-17

Publish Date

2021-06-01

Page Start

133

Page End

142

Print ISSN

2682-261X

Online ISSN

2682-2628

Article File

JCBR_Volume 5_Issue 2_Pages 133-142.pdf

PDF . 2.8MB

Link

https://jcbr.journals.ekb.eg/article_114305.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=114305

Order

12

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

International Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023